Despite 15+ years of research, no cerebral palsy stem cell therapy has received FDA approval in 2026. This guide helps families distinguish experimental neurological treatments from proven orthopedic interventions that address musculoskeletal complications of CP today.

While stem cell therapy for peripheral neuropathy remains experimental and FDA-unapproved in 2026, patients often overlook evidence-based treatments for the tangible musculoskeletal complications they face daily. This article separates experimental promises from clinically proven solutions for neuropathy-related complications.